Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Subscribe To Our Newsletter & Stay Updated